妊娠期注意缺陷多动障碍的管理。

Management of Attention Deficit Hyperactivity Disorder During Pregnancy.

机构信息

Perinatal and Reproductive Psychiatry Program, Harvard Medical School, Massachusetts General Hospital, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA.

Perinatal and Reproductive Psychiatry Program, Harvard Medical School, CTNI, Women's Mental Health, Massachusetts General Hospital, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA.

出版信息

Obstet Gynecol Clin North Am. 2018 Sep;45(3):495-509. doi: 10.1016/j.ogc.2018.04.010.

DOI:10.1016/j.ogc.2018.04.010

PMID:30092924

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder affecting 3.2% of women. More women are taking psychostimulant medications, including during pregnancy. Although stimulant use does not appear to be associated with congenital malformations, there are inconsistent data about other obstetric risks, and no long-term neurodevelopmental data exist to inform clinical management decisions. This article summarizes the available data regarding perinatal exposure to psychostimulants. It also highlights the importance of the risk-risk analysis for clinicians and patients to consider, weighing risks of medication exposure to risks of ADHD during pregnancy, including driving safety and major impairment in occupational roles.

摘要

注意缺陷多动障碍（ADHD）是一种常见的神经行为障碍，影响 3.2%的女性。越来越多的女性在服用精神兴奋剂类药物，包括怀孕期间。虽然兴奋剂的使用似乎与先天性畸形无关，但其他产科风险的数据不一致，也没有长期的神经发育数据来为临床管理决策提供信息。本文总结了围产期暴露于精神兴奋剂的现有数据。它还强调了风险-风险分析对临床医生和患者的重要性，需要权衡药物暴露的风险与怀孕期间 ADHD 的风险，包括驾驶安全和职业角色的严重障碍。